SecBot SecBot
6-K ·Filed Aug 3, 2026

CGEN

COMPUGEN LTD
NEUTRAL
Impact 4/10
Horizonmonths Processed3mo ago SEC0001178913-26-003754
Notable filing: 6-K
Actionable Insight • Neutral

The next significant catalyst is MAIA-ovarian interim PFS data in Q1 2027. With ample cash runway, no near-term dilution expected despite $100M ATM remaining. Monitor enrollment updates and any pipeline expansion announcements. The stock may drift with broader biotech sentiment until data readout.

DirectionNeutral
Confidencemedium
Horizonmonths

COM701

◆ Mixed Named in this 6-K
Impact
Phase
Phase 1/2
Time to market
At least 3-5 years. COM701 is in Phase 1/2 (MAIA trial); even with positive interim data in Q1 2027, a registrational Phase 3 trial and FDA review would follow, putting potential approval in the 2029-2031 timeframe.
Next catalyst
None dated

What to watchThe next hard catalyst for COM701 is the MAIA-ovarian interim PFS analysis expected by Q1 2027, roughly 4-6 months out. Positive data could drive a significant re-rating given the strong analyst consensus (10 Buy/Strong Buy vs 1 Hold) and ~41% implied upside to the $4.60 mean price target. Negative data would be a major setback for Compugen's wholly-owned pipeline. Monitor for any pre-announcements or delays.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$2.38
T+0 close · Aug 3, 2026 · via day close
Latest settled
−18.70%
T+60 · $1.94
Vs SPY
−20.48%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 3 $2.38entry
  2. T+1 · 4mo ago 0.00%α −1.80% · $2.38
  3. T+5 · 3mo ago −1.68%α −3.71% · $2.34
  4. T+20 · 3mo ago +7.56%α +6.33% · $2.56
  5. T+60 · 21d ago −18.70%α −20.48% · $1.94
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Compugen reported Q2 2026 results broadly in line with expectations. Revenue rose 35% YoY to $4.8M (H1) driven by Gilead license recognition, while net loss remained flat at ~$14.7M. Pipeline milestones unchanged: MAIA-ovarian PFS data expected Q1 2027, rilvegostomig OS data presented at ASCO, and GS-0321 Phase 1 on track. Cash position of $125.3M with no debt provides runway into 2029, reducing near-term financing risk.

Key Facts

  • Cash and marketable securities of $125.3M as of June 30, 2026, with no debt and runway into 2029
  • MAIA-ovarian interim PFS analysis for COM701 expected by Q1 2027
  • Rilvegostomig (AZ-partnered) showed first OS readout: median 16.8 months in 1L biliary tract cancer
  • GS-0321 (Gilead-partnered) Phase 1 dose-escalation continuing as planned
  • H1 2026 revenue $4.8M (+35% YoY), net loss $14.7M (flat YoY), cash used in ops $21.9M

Financial Impact

Revenue growth to $4.8M from $3.5M driven by Gilead license revenue; net loss stable at $14.7M; cash position $125.3M down from $145.6M at year-end 2025

revenuecashoperating loss

Risk Factors

  • MAIA-ovarian trial failure or delayed data readout
  • Potential dilution from $100M ATM facility if cash burn accelerates
  • Reliance on partnered programs (AstraZeneca, Gilead) for future milestones
  • Israel geopolitical risk to operations

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001178913-26-003754
Exhibit: exhibit_99-1.htm0001178913-26-003754
Exhibit: exhibit_99-3.htm0001178913-26-003754
Document: zk2635762.htm0001178913-26-003754
Document: 0001178913-26-003754-index-headers.html0001178913-26-003754
Document: 0001178913-26-003754-index.html0001178913-26-003754
Document: 0001178913-26-003754.txt0001178913-26-003754

US Market Status

Market Closed · Opens in 6h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 3, 2026